medigraphic.com
Instituto Nacional de Salud Pública

2019, Número 3

<< Anterior Siguiente >>

salud publica mex 2019; 61 (3)


Características del cáncer de pulmón de células no pequeñas: diferencias por sexo y estado hormonal en una población mexicana

Rodríguez-Lara, Vianey; Ramírez-Tirado, Laura Alejandra; Barrón, Feliciano; Zatarain-Barrón, Zyanya Lucía; Flores-Estrada, Diana; Arrieta, Oscar

Idioma: Ingles.
Referencias bibliográficas: 42
Paginas: 265-275
Archivo PDF: 426.36 Kb.


RESUMEN

Objetivo. Analizar las diferencias en las características clínico-patológicas, moleculares y en la evolución del cáncer de pulmón de células no pequeñas (CPCNP) por sexo y estadio hormonal. Material y métodos. Estudio retrospectivo (N=1 104) en pacientes con CPCNP. Se recabaron datos clínico-patológicos y desenlaces de sobrevida y se compararon entre hombres y mujeres, y entre mujeres pre y postmenopáusicas. Resultados. Las mujeres de este estudio tuvieron significativamente mayor probabilidad de ser no fumadoras (p‹0.001), tener exposición a humo de leña (p‹0.001), mutaciones en EGFR (p‹0.001), mejor estado funcional (p=0.020), y una mejor sobrevida global (SG) en comparación con los hombres (p=0.021). Estas diferencias también se encontraron en cuestión al estatus hormonal, con las mujeres postmenopáusicas presentando una mayor sobrevida en comparación con las premenopáusicas (31.1 vs. 19.4 meses; p=0.046). Conclusión. Los presentes resultados apoyan las diferencias en la presentación del CPCNP de acuerdo con el sexo y estatus hormonal.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Organización Mundial de la Salud. Cáncer. Ginebra: OMS, 2018. [citado mayo 4, 2018]. Disponible en: http://www.who.int/es/news-room/factsheets/ detail/cancer

  2. Gomez-Dantes H, Lamadrid-Figueroa H, Cahuana-Hurtado L, Silverman- Retana O, Montero P, Gonzalez-Robledo MC, et al. The burden of cancer in Mexico, 1990-2013. Salud Publica Mex. 2016;58(2):118-31. https://doi. org/10.21149/spm.v58i2.7780

  3. Borja-Aburto VH, Davila-Torres J, Rascon-Pacheco RA, Gonzalez- Leon M, Fernandez-Garate JE, Mejia-Rodriguez I, et al. Cancer mortality in the Mexican Social Security Institute, 1989-2013. Salud Publica Mex. 2016;58(2):153-61. https://doi.org/10.21149/spm.v58i2.7784

  4. Hernandez-Garduno E, Ocana-Servin HL. Lung cancer mortality trends in Mexico, 1999-2014. Salud Publica Mex. 2018;60(3):366-9. https://doi. org/10.21149/8730

  5. Tovar-Guzman VJ, Lopez-Antunano FJ, Rodriguez-Salgado N. Trends in mortality from lung cancer in Mexico, 1980-2000. Rev Panam Salud Publica. 2005;17(4):254-62.

  6. Malvezzi M, Bosetti C, Chatenoud L, Rodriguez T, Levi F, Negri E, La Vecchia C. Trends in cancer mortality in Mexico, 1970-1999. Ann Oncol. 2004;15(11):1712-8. https://doi.org/10.1093/annonc/mdh424

  7. Rowell TR, Tarran R. Will chronic e-cigarette use cause lung disease? Am J Physiol Lung Cell Mol Physiol. 2015;309(12):L1398-409. https://doi. org/10.1152/ajplung.00272.2015

  8. Li Y, Shi J, Yu S, Wang L, Liu J, Ren J, et al. Health Economic Evaluation Working Group CSPiUC. Effect of socioeconomic status on stage at diagnosis of lung cancer in a hospital-based multicenter retrospective clinical epidemiological study in China, 2005-2014. Cancer Med. 2017;6(10):2440- 52. https://doi.org/10.1002/cam4.1170

  9. Frumkin H, Samet JM, Radon CA. Cancer J Clin. 2001;51(6):337-44, 322; quiz 345-338. https://doi.org/10.3322/canjclin.51.6.337

  10. Knaul FM, Gonzalez-Pier E, Gomez-Dantes O, Garcia-Junco D, Arreola- Ornelas H, Barraza-Llorens M, et al. The quest for universal health coverage: achieving social protection for all in Mexico. Lancet. 2012;380(9849):1259- 79. https://doi.org/10.1016/S0140-6736(12)61068-X

  11. Gildea TR, DaCosta-Byfield S, Hogarth DK, Wilson DS, Quinn CC. A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. Clinicoecon Outcomes Res. 2017;9:261-9. https://doi. org/10.2147/CEOR.S132259

  12. McGuire A, Martin M, Lenz C, Sollano JA. Treatment cost of nonsmall cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases. J Med Econ. 2015;18(7):525-32. https://doi.org/10.3111/13696998.2015.1032974

  13. Instituto Nacional de Estadística y Geografía. Mortalidad. México: INEGI, 2018. [citado mayo 21, 2018]. Disponible en: https://www.inegi.org. mx/temas/mortalidad/default.html#Informacion_general

  14. Arroyave-Loaiza MG. Grupos relacionados con el diagnóstico: Producto Hospitalario, GRD-IMSS: 2014. Ciudad de México: IMSS, 2016.

  15. Arroyave-Loaiza MG, Amador-Vázquez L, Lara-Gómez JE, Rodríguez- Díaz Ponce MA, Dávila-Torres J. Grupos relacionados con la atención ambulatoria de las enfermedades endocrinas, nutricionales y metabólicas EGRAA. Ciudad de México: IMSS, 2014.

  16. Reynales-Shigematsu LM. Tobacco and cancer: epidemiology and new perspectives of prevention and monitoring in Mexico. Salud Publica Mex. 2016;58(2):251-60. https://doi.org/10.21149/spm.v58i2.7794

  17. American Cancer Society. Cancer Facts & Figures. USA: American Cancer Society, 2018. [citado agosto 22, 2018]. Disponible en: https://www. cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/ annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf

  18. Zhi XY, Zou XN, Hu M, Jiang Y, Jia MM, Yang GH. Increased lung cancer mortality rates in the chinese population from 1973-1975 to 2004-2005: an adverse health effect from exposure to smoking. Cancer. 2015;1:3107- 12. https://doi.org/10.1002/cncr.29603

  19. Boffetta P, La Vecchia C, Levi F, Lucchini F. Mortality patterns and trends for lung cancer and other tobacco-related cancers in the Americas, 1955-1989. Int J Epidemiol. 1993; 22(3):377-84. https://doi. org/10.1093/ije/22.3.377

  20. Borja-Aburto VH, Sousa-Santana V. Environmental and social determinants of health. Work and health in the Americas. Washington DC: PAHO, 2016. [citado mayo 15, 2018]. Disponible en: https://www.paho.org/blogs/ paltex/wp-content/uploads/2016/06/preliminares_english_finkelman.pdf

  21. Alberg AJ, Shopland DR, Cummings KM. The 2014 Surgeon General’s report: commemorating the 50th Anniversary of the 1964 Report of the Advisory Committee to the US Surgeon General and updating the evidence on the health consequences of cigarette smoking. Am J Epidemiol. 2014;179(4):403-12. https://doi.org/10.1093/aje/kwt335

  22. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (INPRFM). Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco 2016-2017: Reporte de Tabaco. CDMX: Secretaría de Salud, 2017. [citado mayo 15, 2018]. Disponible en: https://www.gob.mx/salud%7Cconadic/acciones-yprogramas/ encuesta-nacional-de-consumo-de-drogas-alcohol-y-tabacoencodat- 2016-2017-136758

  23. Arrieta O, Lopez-Mejia M, Macedo-Perez EO, Corona-Cruz JF. Proposals for the prevention of lung cancer in the health system of Mexico. Salud Publica Mex. 2016;58(2):274-8. https://doi.org/10.21149/spm.v58i2.7796

  24. Ruiz-Godoy L, Rizo-Rios P, Sanchez-Cervantes F, Osornio-Vargas A, Garcia-Cuellar C, Meneses Garcia A. Mortality due to lung cancer in Mexico. Lung Cancer. 2007;58(2):184-90. https://doi.org/10.1016/j. lungcan.2007.06.007

  25. Yuan P, Cao JL, Rustam A, Zhang C, Yuan XS, Bao FC, et al. Time-to- Progression of NSCLC from Early to Advanced Stages: An Analysis of data from SEER Registry and a Single Institute. Sci Rep. 2016;6:28477. https:// doi.org/10.1038/srep28477

  26. Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013;2:10. https://doi. org/10.1186/2046-4053-2-10

  27. Knaul FM, Arreola-Ornelas H, Wong R, Lugo-Palacios DG, Mendez- Carniado O. The effect of Seguro Popular de Salud on catastrophic and impoverishing expenditures in Mexico, 2004-2012. Salud Publica Mex. 2018;60(2):130-40. https://doi.org/10.21149/9064

  28. Pichon-Riviere A, Bardach A, Augustovski F, Alcaraz A, Reynales-Shigematsu LM, Pinto MT, et al. Financial impact of smoking on health systems in Latin America: A study of seven countries and extrapolation to the regional level. Rev Panam Salud Publica. 2016;40(4):213-221.

  29. Valdes-Salgado R, Avila-Tang E, Stillman FA, Wipfli H, Samet JM. Leyes que prohiben fumar en espacios cerrados en México. Salud Publica Mex. 2008;50(supl 3):S334-42. trials. J Clin Oncol. 2007;25(suppl 18):7549. https://doi.org/10.1200/ jco.2007.25.18_suppl.7549 22. Rodriguez-Lara V, Pena-Mirabal E, Baez-Saldana R, Esparza-Silva AL, Garcia-Zepeda E, Cerbon Cervantes MA, et al. Estrogen receptor beta and CXCR4/CXCL12 expression: differences by sex and hormonal status in lung adenocarcinoma. Arch Med Res. 2014;45(2):158-69. https://doi. org/10.1016/j.arcmed.2014.01.001 23. Wong MCS, Lao XQ, Ho KF, Goggins WB, Tse SLA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7:14300. https://doi.org/10.1038/s41598-017-14513-7 24. Lumsden MA, Davies M, Sarri G, for the Guideline Development Group for Menopause: Diagnosis and Management (NICE Clinical Guideline No. 23). Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline. JAMA Intern Med. 2016;176(8):1205-6. https://doi.org/10.1001/jamainternmed.2016.2761 25. World Health Organization. Guidelines for Controlling and Monitoring the Tobacco Epidemic. Geneva: WHO, 1998. 26. Arrieta O. Suppl files characteristics of non-small cell lung cancer. Differences by sex and hormonal status in a Mexican population. Dataverse 2019. https://doi.org/10.7910/DVN/PAVQ3T 27. Arrieta O, Martinez-Barrera L, Trevino S, Guzman E, Castillo-Gonzalez P, Rios-Trejo MA, et al. Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J Thorac Oncol. 2008;3(8):887-93. https://doi. org/10.1097/JTO.0b013e31818026f6 28. Hernandez-Garduno E, Brauer M, Perez-Neria J, Vedal S. Wood smoke exposure and lung adenocarcinoma in non-smoking Mexican women. Int J Tuberc Lung Dis. 2004;8(3):377-83. 29. Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017;8:98384-93. https://doi.org/10.18632/oncotarget.21842

  30. Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8:75712-26. https://doi.org/10.18632/oncotarget.20095

  31. Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, et al. The influence of body mass index on overall survival following surgical resection of non-small cell lung cancer. J Thorac Oncol. 2017;12(8):1280-7. https://doi.org/10.1016/j.jtho.2017.05.010

  32. Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res. 2008;14(14):4417-26. https://doi. org/10.1158/1078-0432.CCR-07-1950

  33. Mah V, Marquez D, Alavi M, Maresh EL, Zhang L, Yoon N, et al. Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer. 2011;74(2):318-25. https://doi.org/10.1016/j.lungcan.2011.03.009

  34. Deng F, Li M, Shan WL, Qian LT, Meng SP, Zhang XL, Wang BL. Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-beta in advanced non-small cell lung cancer. Oncol Lett. 2017;13(4):2359-65. https://doi.org/10.3892/ol.2017.5711

  35. Chen XQ, Zheng LX, Li ZY, Lin TY. Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer. J Int Med Res. 2017;45(1):51-8. https://doi.org/10.1177/0300060516666229

  36. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005;65(4):1459-70. https://doi.org/10.1158/0008- 5472.CAN-04-1872

  37. Giovannini M, Belli C, Villa E, Gregorc V. Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case? J Thorac Oncol. 2008;3(3):684-5. https://doi. org/10.1097/JTO.0b013e3181757aec

  38. Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci. 2009;1155(1):194-205. https://doi.org/10.1111/ j.1749-6632.2009.04116.x

  39. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 2009;27(3):411-7. https://doi.org/10.1200/ JCO.2008.18.3251

  40. Tang H, Liao Y, Zhang C, Chen G, Xu L, Liu Z, et al. Fulvestrantmediated inhibition of estrogen receptor signaling slows lung cancer progression. Oncol Res. 2014;22(1):13-20. https://doi.org/10.3727/096504 014X14077751730315

  41. Wen S, Fu X, Li G, He L, Zhao C, Hu X, et al. Efficacy of tamoxifen in combination with docetaxel in patients with advanced non-small-cell lung cancer pretreated with platinum-based chemotherapy. Anticancer Drugs. 2016;27(5):447-56. https://doi.org/10.1097/CAD.0000000000000350

  42. Rosell J, Nordenskjold B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, et al. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen. Acta Oncol. 2017;56(4):614-7. https://doi.org/10.1080/028418 6X.2016.1273547




2020     |     www.medigraphic.com